{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T08:05:07Z","timestamp":1779869107214,"version":"3.53.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW 113-CDC-C-114-000107"],"award-info":[{"award-number":["MOHW 113-CDC-C-114-000107"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jmii.2025.08.024","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:10:27Z","timestamp":1756336227000},"page":"310-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world viral effectiveness of two-drug versus three-drug regimens for HIV in Taiwan: Impact of adherence and treatment selection"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7188-2813","authenticated-orcid":false,"given":"Tien-Heng","family":"Ku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yu","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-6783","authenticated-orcid":false,"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Huei","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-582X","authenticated-orcid":false,"given":"Shih-Hao","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-8376","authenticated-orcid":false,"given":"Chun-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2025.08.024_bib1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed September 12, 2024."},{"key":"10.1016\/j.jmii.2025.08.024_bib2","article-title":"Low-level viremia predicts virological failure in HIV-Infected Omani patients receiving antiretroviral therapy","volume":"19","author":"Gaifer","year":"2020","journal-title":"J Int Assoc Phys AIDS Care"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.024_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"issue":"s3","key":"10.1016\/j.jmii.2025.08.024_bib4","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1086\/533415","article-title":"Preventing HIV antiretroviral resistance through better monitoring of treatment adherence","volume":"197","year":"2008","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jmii.2025.08.024_bib5","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.4081\/jphia.2023.2434","article-title":"Febriyanti, antiretroviral medication adherence for people with HIV\/AIDS","volume":"14","author":"Supriyatni","year":"2023","journal-title":"J Publ Health Afr"},{"issue":"9","key":"10.1016\/j.jmii.2025.08.024_bib6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/QAD.0000000000003234","article-title":"Estimating the minimum antiretroviral adherence required for plasma HIV-1 RNA viral load suppression among people living with HIV who use unregulated drugs","volume":"36","author":"Stover","year":"2022","journal-title":"Aids"},{"issue":"3","key":"10.1016\/j.jmii.2025.08.024_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","article-title":"Antiretroviral adherence level necessary for HIV viral suppression using real-world data","volume":"82","author":"Byrd","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"10.1016\/j.jmii.2025.08.024_bib8","first-page":"1129","article-title":"Correlation between medication adherence using proportion of days covered and achieving viral suppression in patients living with HIV","volume":"29","author":"Komandt","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jmii.2025.08.024_bib9","article-title":"Real world data on forgiveness to uncomplete adherence to Bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J Int Assoc Phys AIDS Care"},{"key":"10.1016\/j.jmii.2025.08.024_bib10","series-title":"PQA Measure Overview","year":"2024"},{"issue":"10167","key":"10.1016\/j.jmii.2025.08.024_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jmii.2025.08.024_bib12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.08.024_bib13","article-title":"Adherence and forgiveness of two modern ART regimens: lamivudine\/dolutegravir and emtricitabine\/tenofovir alafenamide\/rilpivirine","author":"L","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.024_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/QAI.0000000000001168","article-title":"Brief report: factors associated with the selection of initial antiretroviral therapy from 2009 to 2012","volume":"74","author":"Saag","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2025.08.024_bib15","article-title":"HIV drug resistance in southeast Asia: prevalence, determinants, and strategic management","volume":"6","author":"Chia","year":"2022","journal-title":"J Publ Health Epidemiol"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.024_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph13010030","article-title":"Characterizing the HIV\/AIDS epidemic in the United States and China","volume":"13","author":"Huang","year":"2015","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.jmii.2025.08.024_bib17","series-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach","year":"2021"},{"key":"10.1016\/j.jmii.2025.08.024_bib18","volume":"vol. 21","author":"Maggiolo","year":"2022"},{"issue":"11","key":"10.1016\/j.jmii.2025.08.024_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314003","article-title":"Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV","volume":"19","author":"Lee","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.024_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/25787489.2021.2016303","article-title":"Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate\/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies","volume":"23","author":"Ait-Khaled","year":"2021","journal-title":"HIV Res Clin Pract"},{"key":"10.1016\/j.jmii.2025.08.024_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jgar.2022.07.022","article-title":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study","volume":"31","author":"Santoro","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.024_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/cid\/ciae006","article-title":"Two cases of viral Re-suppression after M184V + R263K selection on dolutegravir\/lamivudine without treatment modification","volume":"79","author":"Ursenbach","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jmii.2025.08.024_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jmii.2025.08.024_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","article-title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","volume":"239","author":"Brenner","year":"2017","journal-title":"Virus Res"},{"issue":"6","key":"10.1016\/j.jmii.2025.08.024_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40121-025-01153-y","article-title":"Efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) after A viremic event: a pooled analysis of studies in people with HIV","volume":"14","author":"Pozniak","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.jmii.2025.08.024_bib26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/QAD.0000000000001772","article-title":"Impact of insurance coverage on HIV transmission potential among antiretroviral therapy-treated youth living with HIV","volume":"32","author":"Wood","year":"2018","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.024_bib27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1186\/s12879-016-2075-0","article-title":"ART access-related barriers faced by HIV-Positive persons linked to care in southern Ghana: a mixed method study","volume":"16","author":"Ankomah","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.jmii.2025.08.024_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF02850081","article-title":"Medication adherence and persistence: a comprehensive review","volume":"22","author":"Krueger","year":"2005","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.jmii.2025.08.024_bib29","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1007\/s10461-020-02937-8","article-title":"Antiretroviral adherence, drug resistance, and the impact of social determinants of health in HIV-1 patients in the US","volume":"24","author":"Benson","year":"2020","journal-title":"AIDS Behav"},{"issue":"9","key":"10.1016\/j.jmii.2025.08.024_bib30","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","article-title":"Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States","volume":"38","author":"McComsey","year":"2021","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jmii.2025.08.024_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/ejhpharm-2022-003277","article-title":"Real-world effectiveness and durability of dual antiretroviral therapy in HIV-infected patients","volume":"31","author":"P\u00e9rez-Cord\u00f3n","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.jmii.2025.08.024_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5804","article-title":"Non-adherence and non-persistence with antiretroviral treatment in Belgium: a real-world evaluation using a pharmacy database, 2018-2021","volume":"33","author":"Ilboudo","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:27:54Z","timestamp":1779866874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225001823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1684118225001823"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.08.024","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world viral effectiveness of two-drug versus three-drug regimens for HIV in Taiwan: Impact of adherence and treatment selection","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}